Zamtocabtagene autoleucel

{
  "id": "MLC-T-ONC-017649",
  "term": "Zamtocabtagene autoleucel",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous CD4/CD8 enriched T lymphocytes engineered to express pLTG1497, a tandem chimeric antigen receptor (CAR) specific for the two tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19) and CD20, with potential immunostimulating and antineoplastic activities. Upon administration, zamtocabtagene autoleucel target and bind to CD19- and CD20-expressing tumor B cells. This induces selective toxicity in tumor B-cells expressing these TAAs. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies. Targeting both CD19 and CD20 may prevent tumor cell antigen escape and relapse.",
  "synonyms": [
    "autologous pLTG1497-transduced CAR T cells MB-CART2019.1",
    "autologous anti-CD20/CD19-targeting tandem CAR T cells MB-CART2019.1"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/zamtocabtagene-autoleucel/"
}